Ventech

Ventech, established in 1998, is a prominent venture capital firm headquartered in Paris, with additional offices in Munich, Helsinki, and Shanghai. The company manages multiple funds, totaling over USD 1 billion in assets under management. Ventech invests in early-stage startup companies across various sectors, including software, technology, media, and telecommunications (TMT), with a broad investment scope encompassing both B2B and B2C models, and hardware and software solutions. Geographically, Ventech focuses on Europe, with a particular emphasis on France, the DACH region, and the Nordics, while its Shanghai office targets investments in Asia. Notable portfolio companies of Ventech China include Keep, WonderFull, Juzi, Datawin, and Blued. The firm is committed to supporting innovative startups and helping them grow into global leaders in their respective fields.

Nicolas Barthalon

Principal

Jean Bourcereau

President

Alain Caffi

Founding Partner

Christian Claussen

General Partner

Curtis Ferguson

Managing Partner

Charles Fourault

Partner

Claire Houry

General Partner

Eric Huet

Founding Partner

Zhiren Mao

Associate

Karen Pan

Analyst

Audrey Soussan

Managing Partner

Michelle Sung

Partner

Chris Tan

Analyst

Joel Uddén

Principal

Eunice Wang

Vice President

Stephan Wirries

Partner

Harvey Yang

Partner

Past deals in Austria

Prewave

Series B in 2024
Prewave GmbH is a technology company based in Vienna, Austria, that specializes in developing machine learning solutions for supply chain risk management. Founded in 2017, Prewave's platform utilizes advanced data analytics to analyze social media data, allowing businesses to monitor for potential supply chain anomalies. By predicting upcoming risk events, the platform helps companies enhance their logistics networks and identify sustainability challenges. Through its innovative approach, Prewave aims to provide organizations with insights that enable them to proactively address risks within their supply chains.

Prewave

Series A in 2023
Prewave GmbH is a technology company based in Vienna, Austria, that specializes in developing machine learning solutions for supply chain risk management. Founded in 2017, Prewave's platform utilizes advanced data analytics to analyze social media data, allowing businesses to monitor for potential supply chain anomalies. By predicting upcoming risk events, the platform helps companies enhance their logistics networks and identify sustainability challenges. Through its innovative approach, Prewave aims to provide organizations with insights that enable them to proactively address risks within their supply chains.

Prewave

Series A in 2022
Prewave GmbH is a technology company based in Vienna, Austria, that specializes in developing machine learning solutions for supply chain risk management. Founded in 2017, Prewave's platform utilizes advanced data analytics to analyze social media data, allowing businesses to monitor for potential supply chain anomalies. By predicting upcoming risk events, the platform helps companies enhance their logistics networks and identify sustainability challenges. Through its innovative approach, Prewave aims to provide organizations with insights that enable them to proactively address risks within their supply chains.

Prewave

Seed Round in 2020
Prewave GmbH is a technology company based in Vienna, Austria, that specializes in developing machine learning solutions for supply chain risk management. Founded in 2017, Prewave's platform utilizes advanced data analytics to analyze social media data, allowing businesses to monitor for potential supply chain anomalies. By predicting upcoming risk events, the platform helps companies enhance their logistics networks and identify sustainability challenges. Through its innovative approach, Prewave aims to provide organizations with insights that enable them to proactively address risks within their supply chains.

Themis Bioscience

Series D in 2019
Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Themis Bioscience

Series C in 2018
Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Themis Bioscience

Series B in 2016
Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Asgoodasnew

Series C in 2015
Asgoodasnew electronics GmbH is a leading provider of refurbished consumer electronics in Europe. The company operates an online retail platform that offers a wide range of gadgets, including cellphones, music players, portable navigation systems, computers, smart accessories, and gaming devices. Through its trade-in services, such as WIRKAUFENS in Germany and Austria, LOCOMPRAMOS in Spain, and KUPIMYTO in Poland, Asgoodasnew allows customers to easily and securely convert their used electronics into cash. By selling refurbished products both directly to consumers and businesses, Asgoodasnew aims to provide affordable alternatives to new devices while maintaining the quality and reliability that consumers expect.

Asgoodasnew

Series B in 2012
Asgoodasnew electronics GmbH is a leading provider of refurbished consumer electronics in Europe. The company operates an online retail platform that offers a wide range of gadgets, including cellphones, music players, portable navigation systems, computers, smart accessories, and gaming devices. Through its trade-in services, such as WIRKAUFENS in Germany and Austria, LOCOMPRAMOS in Spain, and KUPIMYTO in Poland, Asgoodasnew allows customers to easily and securely convert their used electronics into cash. By selling refurbished products both directly to consumers and businesses, Asgoodasnew aims to provide affordable alternatives to new devices while maintaining the quality and reliability that consumers expect.

Themis Bioscience

Series A in 2011
Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Asgoodasnew

Series A in 2011
Asgoodasnew electronics GmbH is a leading provider of refurbished consumer electronics in Europe. The company operates an online retail platform that offers a wide range of gadgets, including cellphones, music players, portable navigation systems, computers, smart accessories, and gaming devices. Through its trade-in services, such as WIRKAUFENS in Germany and Austria, LOCOMPRAMOS in Spain, and KUPIMYTO in Poland, Asgoodasnew allows customers to easily and securely convert their used electronics into cash. By selling refurbished products both directly to consumers and businesses, Asgoodasnew aims to provide affordable alternatives to new devices while maintaining the quality and reliability that consumers expect.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.